Clinical Trial Details

If you are a patient or a caregiver and would like to learn more our cancer clinical trials
call toll-free 1-855-702-8222 (adult trials) or 1-773-702-6808 (pediatric trials) or
email cancerclinicaltrials@bsd.uchicago.edu.

Phase 3 Study of DCC-2618 vs Placebo in Advanced GIST Patients Who Have Been Treated With Prior Anticancer Therapies

Official Title

A Phase 3, INterVentional, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of DCC-2618 In Patients With AdvanCed Gastrointestinal Stromal TUmorS Who Have Received Treatment With Prior Anticancer Therapies

Principal Investigator

Kindler, Hedy

Brief Summary

This is a 2‑arm, randomized, placebo-controlled, double‑blind, international, multicenter
study comparing the efficacy of DCC-2618 to placebo in patients who have received treatment
with prior anticancer therapies. Prior anticancer therapies must include imatinib, sunitinib,
and regorafenib (3 prior therapies). Approximately 120 patients will be randomized in a 2:1
ratio to DCC‑2618 150 mg QD or placebo